CA2376886A1 - Therapeutic agents - Google Patents

Therapeutic agents Download PDF

Info

Publication number
CA2376886A1
CA2376886A1 CA002376886A CA2376886A CA2376886A1 CA 2376886 A1 CA2376886 A1 CA 2376886A1 CA 002376886 A CA002376886 A CA 002376886A CA 2376886 A CA2376886 A CA 2376886A CA 2376886 A1 CA2376886 A1 CA 2376886A1
Authority
CA
Canada
Prior art keywords
triazolo
ethyl
pyrimidine
chlorophenoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376886A
Other languages
English (en)
French (fr)
Inventor
Ian Charles Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of CA2376886A1 publication Critical patent/CA2376886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002376886A 1999-06-24 2000-06-16 Therapeutic agents Abandoned CA2376886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9914743.1A GB9914743D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
GB9914743.1 1999-06-24
PCT/EP2000/005543 WO2001000186A2 (en) 1999-06-24 2000-06-16 New use of 1,2,4-triazolo'1,5-a! pyrimidines

Publications (1)

Publication Number Publication Date
CA2376886A1 true CA2376886A1 (en) 2001-01-04

Family

ID=10855954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376886A Abandoned CA2376886A1 (en) 1999-06-24 2000-06-16 Therapeutic agents

Country Status (7)

Country Link
EP (1) EP1218008A2 (ja)
JP (1) JP2003503343A (ja)
AU (1) AU6150200A (ja)
CA (1) CA2376886A1 (ja)
GB (1) GB9914743D0 (ja)
MX (1) MXPA01013421A (ja)
WO (1) WO2001000186A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2743299A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
US8759357B2 (en) 2009-10-08 2014-06-24 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy

Also Published As

Publication number Publication date
EP1218008A2 (en) 2002-07-03
GB9914743D0 (en) 1999-08-25
AU6150200A (en) 2001-01-31
MXPA01013421A (es) 2002-07-30
WO2001000186A3 (en) 2002-05-10
WO2001000186A2 (en) 2001-01-04
JP2003503343A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
US20190152991A1 (en) Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
EP0723546B1 (en) 1,2,4 - TRIZOLO[1,5-a]PYRIMIDINE AND THEIR USE FOR TREATMENT OF NEUROLOGICAL DISORDERS
US8198320B2 (en) Hypoglycemic activity of osthole
EP2696864A1 (en) Therapeutic compounds
PL208138B1 (pl) Zastosowanie kompozycji farmaceutycznej
EP0682947B1 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
US5962523A (en) Methods of using butyric acid derivatives to protect against hair loss
US6852756B1 (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
CA2376886A1 (en) Therapeutic agents
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
EP1218010A2 (en) 1,4-benzothiazepines to treat obesity related disorders
JPS60158149A (ja) 炎症抑制作用を有する１，４‐ナフトキノン誘導体
JP7520810B2 (ja) 医薬製剤
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
JP2002539261A (ja) ピリミジン誘導体とシクロデキストリンを含有する医薬組成物
WO2000056292A2 (en) Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
CN113679725A (zh) 一种头孢类化合物及其在制备治疗糖尿病和并发症药物中的应用
JPH07138226A (ja) 新規な血行促進のために使用する医薬
WO2011034462A1 (ru) Комбинированный противотуберкулезный препарат
JP2003267871A (ja) 放射線障害予防剤
JPH10109936A (ja) 糖尿病性神経障害の治療・予防剤
JP2001213783A (ja) 動物用治療剤

Legal Events

Date Code Title Description
FZDE Dead